2seventy bio Stock (NASDAQ:TSVT)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$3.16

52W Range

$1.68 - $6.40

50D Avg

$4.59

200D Avg

$4.63

Market Cap

$185.91M

Avg Vol (3M)

$309.30K

Beta

1.79

Div Yield

-

TSVT Company Profile


2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

274

IPO Date

Nov 03, 2021

Website

TSVT Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
Service---
Royalty And Other Revenue---
Collaboration Arrangement---

Fiscal year ends in Dec 23 | Currency in USD

TSVT Financial Summary


Dec 23Dec 22Dec 21
Revenue---
Operating Income---
Net Income---
EBITDA---
Basic EPS---
Diluted EPS---

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Nov 12, 24 | 11:16 AM
Q2 24Aug 11, 24 | 4:52 AM
Q1 24May 08, 24 | 12:00 AM

Peer Comparison


TickerCompany
DICEDICE Therapeutics, Inc.
PLRXPliant Therapeutics, Inc.
CGEMCullinan Oncology, Inc.
ZNTLZentalis Pharmaceuticals, Inc.
IOVAIovance Biotherapeutics, Inc.
RCUSArcus Biosciences, Inc.
DAWNDay One Biopharmaceuticals, Inc.
PHATPhathom Pharmaceuticals, Inc.
STOKStoke Therapeutics, Inc.
SRPTSarepta Therapeutics, Inc.
RLAYRelay Therapeutics, Inc.
REPLReplimune Group, Inc.
KDNYChinook Therapeutics, Inc.
SNDXSyndax Pharmaceuticals, Inc.
INZYInozyme Pharma, Inc.
CRNXCrinetics Pharmaceuticals, Inc.
ASNDAscendis Pharma A/S
PBYIPuma Biotechnology, Inc.
MRSNMersana Therapeutics, Inc.
KZRKezar Life Sciences, Inc.
PTGXProtagonist Therapeutics, Inc.